心脉医疗（688016）披露2025年年度业绩快报公告，2月27日股价下跌0.12%

Core Viewpoint - Shanghai MicroPort CardioFlow Medtech Co., Ltd. reported a strong financial performance for the year 2025, with significant growth in revenue and net profit, indicating a positive outlook for the company and its market position [1]. Financial Performance - The company achieved total revenue of 1.351 billion yuan, representing a year-on-year increase of 11.96% [1]. - The net profit attributable to shareholders was 563 million yuan, up 12.17% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 502 million yuan, reflecting a substantial growth of 26.97% [1]. - Basic earnings per share reached 4.65 yuan, an increase of 14.25% compared to the previous year [1]. Asset and Equity Growth - Total assets amounted to 4.640 billion yuan, showing an 8.13% increase from the beginning of the year [1]. - The equity attributable to shareholders of the parent company was 4.076 billion yuan, which is a 7.48% growth since the start of the year [1]. Market Expansion - The company has accelerated its overseas market expansion, with overseas revenue exceeding 250 million yuan, marking a growth of over 55% [1]. - Products are now sold in 49 countries and regions, indicating a broadening international presence [1].